Digbi Health Launches GLP-Fit™, Expanding Its Precision Biology Platform to GLP-1 Based Personalized Obesity Care

PALO ALTO, Calif., September 28, 2023 /Digbi Newswire/ -- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs — obesity, type 2 diabetes and digestive health — today announced Digbi GLP-Fit™, a scientifically backed approach to identifying the best treatment path for an individual to prevent and treat obesity.

Key highlights

• GLP-Fit™ uses precision biology to identify the best obesity treatment path for an individual with 87% accuracy: precision nutrition alone; precision nutrition combined with lower-cost drugs such as Metformin; or precision nutrition combined with GLP-1 medications.
• For Pharmacy Benefit Managers, GLP-Fit™ streamlines prior authorization for GLP-1 obesity management drugs, reducing member friction and generating multi-million dollar savings for health plans and employers.
• The program guarantees 100% financial ROI, providing tangible savings for employers, PBMs and health plans while ensuring medically safe patient care.

The science behind GLP-Fit™

The approach integrates genetics, gut microbiome and continuous glucose monitoring insights to recommend a care path and deliver personalized obesity treatment. Unlike digital programs that rely exclusively on behavior change, GLP-Fit™ builds on recognition by the National Institutes of Health and research institutions including Harvard Health that genetics account for up to 80% of obesity risk, and that insulin resistance and the gut microbiome are essential factors in addressing obesity.

Sustainable, effective care

The personalized approach offers substantial savings for employers and payers, and ensures individuals are not placed on lifelong GLP-1 treatment unnecessarily — aligning with Digbi Health's prevention and effective-care mission.

We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic. Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.

— Ranjan Sinha, CEO, Digbi Health

Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.

The five-point GLP-Fit™ difference

• Precision diagnostics — genetics, gut microbiome and CGM combine into a bio-digital twin view of an individual's health.
• Risk assessment — 300 gene variants inform a polygenic risk score for weight regain, evaluated alongside gut microbiome and insulin metabolism.
• Precision biology-based lifestyle support — the FDA requires GLP drugs to be accompanied by nutrition and lifestyle support.
• Proven and patented de-prescription path — a clinically safe, personalized tapering plan for GLP drugs.
• Gut microbiome informed care — the microbiome is monitored every 120 days; a longer tapering period is considered if it has not shifted to a less obesogenic state.

Originally distributed via Business Wire.